Clinical Trial Update: 5HT3 Antagonism and Auditory Gating in Schizophrenia [NA]

View source ↗

Summary

A completed clinical trial update evaluating 5-HT3 receptor antagonism and auditory gating in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: US Department of Veterans Affairs | Conditions: Schizophrenia | NA | Status: COMPLETED